KOD Stock Price, Kodiak Sciences Inc Quote, Chart

Market Summary

USD3.86-0.55

Market Closed

-12.47%

KOD Stock Price

View Fullscreen

KOD RSI Chart

KOD Valuation

Market Cap

202.7M

Price/Earnings (Trailing)

-0.78

Price/Free Cashflow

-1.04

KOD Price/Sales (Trailing)

KOD Profitability

Return on Equity

-98.01%

Return on Assets

-54.34%

Free Cashflow Yield

-96.47%

KOD Fundamentals

KOD Earnings

Earnings (TTM)

-260.5M

Earnings Growth (Yr)

15.52%

Earnings Growth (Qtr)

-19.02%

Breaking Down KOD Revenue

Last 7 days

-10.0%

Last 30 days

-34.1%

Last 90 days

16.6%

Trailing 12 Months

-22.8%

How does KOD drawdown profile look like?

KOD Financial Health

Current Ratio

6.93

KOD Investor Care

Shares Dilution (1Y)

0.33%

Diluted EPS (TTM)

-4.97

Tracking the Latest Insider Buys and Sells of Kodiak Sciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jun 16, 2023	ehrlich jason	sold	-20,841	9.23	-2,258	see remarks
Jun 16, 2023	borgeson john a.	sold	-25,373	9.23	-2,749	see remarks
Jun 15, 2023	borgeson john a.	acquired	-	-	5,494	see remarks
Jun 15, 2023	ehrlich jason	acquired	-	-	5,494	see remarks
Jun 14, 2023	ehrlich jason	sold	-10,663	9.42	-1,132	see remarks
Jun 14, 2023	borgeson john a.	sold	-13,640	9.42	-1,448	see remarks
Jun 11, 2023	ehrlich jason	acquired	-	-	2,900	see remarks
Jun 11, 2023	borgeson john a.	acquired	-	-	3,025	see remarks
Dec 30, 2022	perlroth victor	gifted	-	-	-60,000	chairman and ceo
Jun 17, 2022	ehrlich jason	sold	-16,019	7.02	-2,282	see remarks

Which funds bought or sold KOD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Apr 05, 2024	GAMMA Investing LLC	new	-	5,581	5,581	-%
Apr 05, 2024	LOS ANGELES CAPITAL MANAGEMENT LLC	reduced	-14.00	228,642	697,103	-%
Mar 28, 2024	Newbridge Financial Services Group, Inc.	sold off	-100	-14.00	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	new	-	605	605	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.64	2,056,720	4,996,150	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	80.89	1,609,430	2,392,600	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.4	19,876	49,011	-%
Feb 16, 2024	PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO	unchanged	-	7,486	17,486	-%
Feb 15, 2024	BARCLAYS PLC	added	61.34	196,000	310,000	-%

Are Funds Buying or Selling KOD?

Are funds buying KOD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own KOD

No. of Funds

Unveiling Kodiak Sciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	perlroth victor	10.4%	5,758,427	SC 13G/A
Jan 26, 2024	blackrock inc.	7.7%	4,032,822	SC 13G/A
Feb 14, 2023	perlroth victor	12.2%	6,691,321	SC 13G/A
Feb 14, 2023	price t rowe associates inc /md/	0.9%	472,013	SC 13G/A
Feb 09, 2023	vanguard group inc	3.17%	1,657,156	SC 13G/A
Feb 03, 2023	blackrock inc.	8.2%	4,287,809	SC 13G
Jun 06, 2022	baker bros. advisors lp	33.4%	17,353,846	SC 13D/A
May 18, 2022	baker bros. advisors lp	31.6%	16,431,091	SC 13D/A
Mar 10, 2022	wellington management group llp	3.20%	1,654,396	SC 13G/A
Mar 10, 2022	price t rowe associates inc /md/	5.1%	2,685,747	SC 13G/A

Recent SEC filings of Kodiak Sciences Inc

View All Filings

Date Filed	Form Type	Document
Mar 28, 2024	S-8	Employee Benefits Plan
Mar 28, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Jan 26, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Kodiak Sciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.7B	6.8B	0.01%	-33.89%	-8.42	5.79	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.06%	-27.57%	-42.25	10.17	76.23%	61.08%
BMRN	17.3B	2.4B	9.12%	-7.56%	103	7.14	15.42%	18.43%
INCY	12.0B	3.7B	-8.48%	-28.30%	20.07	3.25	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-9.27%	-36.41%	-11.74	15.65	425.83%	18.94%
BBIO	4.5B	-	-6.46%	74.90%	-6.94	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-9.62%	-0.34%	-13.52	11.95	440.80%	-27.84%
ARWR	3.0B	240.7M	-15.06%	-21.14%	-10.03	12.36	-1.03%	-92.09%
ACAD	2.8B	726.4M	-8.60%	-6.11%	-45.41	3.83	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.17%	-12.95%	25.42	4.56	85.90%	-14.05%
NVAX	576.6M	983.7M	-22.12%	-55.02%	-1.06	0.59	-50.36%	17.16%
CRBP	448.6M	881.7K	-2.13%	345.78%	-10.06	466.16	-77.61%	-5.33%
INO	256.8M	4.9M	2.33%	7.75%	-1.9	52.78	-54.97%	51.72%
IBIO	6.7M	2.1M	82.86%	81.13%	-0.25	2.14	-13.45%	66.37%

Kodiak Sciences Inc News

Latest updates

Kodiak Sciences Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-12.5%	479	548	590	640	667	724	782	850	904	958	998	1,033	1,067	481	429	443	359	69.00	78.00	87.00	92.00
Current Assets	-17.6%	289	351	387	431	486	545	604	682	735	806	884	932	972	382	419	425	339	61.00	70.00	83.00	90.00
Cash Equivalents	-17.4%	286	346	379	317	190	178	173	672	732	799	881	920	944	292	270	226	212	37.00	45.00	57.00	88.00
Net PPE	-3.8%	120	125	130	135	56.00	56.00	55.00	49.00	41.00	23.00	9.00	7.00	5.00	4.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	-12.9%	214	245	251	248	230	244	251	253	241	232	218	211	207	199	120	115	14.00	9.00	8.00	7.00	5.00
Current Liabilities	-41.0%	42.00	71.00	74.00	69.00	52.00	66.00	70.00	76.00	65.00	54.00	41.00	35.00	31.00	23.00	19.00	14.00	12.00	7.00	6.00	5.00	5.00
Shareholder's Equity	-12.1%	266	302	338	393	436	480	531	597	663	726	779	822	861	282	309	328	345	60.00	70.00	80.00	87.00
Retained Earnings	-5.4%	-1,152	-1,093	-1,043	-962	-892	-821	-744	-653	-558	-465	-397	-341	-291	-244	-208	-182	-158	-142	-130	-118	-110
Additional Paid-In Capital	1.6%	1,418	1,395	1,381	1,355	1,330	1,304	1,277	1,251	1,222	1,191	1,177	1,163	1,152	526	517	510	503	202	200	199	198
Shares Outstanding	0.1%	53.00	52.00	52.00	52.00	52.00	52.00	52.00	52.00	52.00	52.00	52.00	52.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	243	-	-	-	3,100	-	-	-	1,600	-	-	-	274	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	1.6%	-32,239	-32,764	-41,959	-47,221	-55,075	-53,087	-55,137	-43,160	-59,035	-51,949	-36,661	-34,625	-27,019	-24,572	-13,905	-17,932	-11,293	-7,696	-12,950	-7,207	-8,340
Share Based Compensation	63.7%	22,829	13,946	25,801	25,980	25,778	26,182	25,978	28,095	27,996	12,377	11,087	9,925	9,455	8,241	6,890	6,082	1,936	1,773	1,244	1,157	1,116
Cashflow From Investing	-12200.0%	-27,798	-226	103,844	173,406	66,998	58,730	-443,952	-18,289	-10,859	-31,705	-5,452	9,218	58,858	56,392	56,781	-67,197	-113,283	-523	680	-23,872	-525
Cashflow From Financing	-933.3%	-124	-12.00	170	-3.00	97.00	78.00	54.00	1,666	2,157	2,031	2,522	1,472	616,281	804	504	99,788	299,340	285	15.00	47.00	85,529

KOD Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating expenses
Research and development	$ 206,298	$ 267,591	$ 217,340
General and administrative	71,023	73,788	49,711
Total operating expenses	277,321	341,379	267,051
Loss from operations	(277,321)	(341,379)	(267,051)
Interest income	16,733	7,071	298
Interest expense	(13)	(18)	(47)
Other income (expense), net	110	503	(190)
Net loss	$ (260,491)	$ (333,823)	$ (266,990)
Net loss per share common share, basic	$ (4.97)	$ (6.39)	$ (5.16)
Net loss per share common share, diluted	$ (4.97)	$ (6.39)	$ (5.16)
Weighted-average shares of common stock outstanding used in computing net loss per common share, basic	52,414,256	52,249,620	51,788,918
Weighted-average shares of common stock outstanding used in computing net loss per common share, diluted	52,414,256	52,249,620	51,788,918
Other comprehensive income (loss)
Change in unrealized gains (losses) related to available-for-sale debt securities, net of tax	$ 1,307	$ (1,307)	$ (53)
Total other comprehensive income (loss)	1,307	(1,307)	(53)
Comprehensive loss	$ (259,184)	$ (335,130)	$ (267,043)

KOD Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 285,507	$ 190,433
Marketable securities	0	288,500
Prepaid expenses and other current assets	3,802	7,072
Total current assets	289,309	486,005
Restricted cash	6,324	6,324
Property and equipment, net	120,482	56,384
Operating lease right-of-use asset	54,541	59,369
Other assets	8,716	58,546
Total assets	479,372	666,628
Current liabilities:
Accounts payable	13,608	9,130
Accrued and other current liabilities	18,351	33,440
Operating lease liability	9,770	9,926
Total current liabilities	41,729	52,496
Operating lease liability, net of current portion	71,862	77,807
Liability related to sale of future royalties	100,000	99,996
Other liabilities	0	162
Total liabilities	213,591	230,461
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.0001 par value, 10,000,000 shares authorized; 0 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	0	0
Common stock, $0.0001 par value, 490,000,000 shares authorized at December 31, 2023 and December 31, 2022; 52,508,602 and 52,333,850 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	5	5
Additional paid-in capital	1,418,307	1,329,509
Accumulated other comprehensive income (loss)	0	(1,307)
Accumulated deficit	(1,152,531)	(892,040)
Total stockholders’ equity	265,781	436,167
Total liabilities and stockholders’ equity	$ 479,372	$ 666,628

About Kodiak Sciences Inc

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naÃƒÂ¯ve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

CEO	Dr. Victor Perlroth M.D.
WEBSITE	https://kodiak.com
INDUSTRY	Biotechnology
EMPLOYEES	118

Kodiak Sciences Inc Frequently Asked Questions

What is the ticker symbol for Kodiak Sciences Inc? What does KOD stand for in stocks?

KOD is the stock ticker symbol of Kodiak Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Kodiak Sciences Inc (KOD)?

As of Mon Apr 15 2024, market cap of Kodiak Sciences Inc is 202.68 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KOD stock?

You can check KOD's fair value in chart for subscribers.

What is the fair value of KOD stock?

You can check KOD's fair value in chart for subscribers. The fair value of Kodiak Sciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Kodiak Sciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KOD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Kodiak Sciences Inc a good stock to buy?

The fair value guage provides a quick view whether KOD is over valued or under valued. Whether Kodiak Sciences Inc is cheap or expensive depends on the assumptions which impact Kodiak Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KOD.